Biofrontera Bioscience GmbH   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Leverkusen Germany (1997)

Organization Overview

First Clinical Trial
2006
NCT02799030
First Marketed Drug
2000
erythromycin (ilosone)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOFRONTERA | Biofrontera Bioscience GmbH

Active Ingredients

Marketed Drugs (3)

aminolevulinic acid (levulan) (2016)

benzoyl peroxide (clearasil) (2000)

erythromycin (ilosone) (2000)

Drugs in Phase 4 Trials (1)

aminolevulinic acid (levulan) (10 trials)

Drugs in Phase 3 Trials (4)

Key: Biofrontera Bioscience GmbH (2) Acquired (2)

ameluz (1 trial)

furosemide (lasix) (6 trials)

methyl aminolevulinate (metvixia) (2 trials)

omiganan (10 trials)

Drugs in Phase 2 Trials (4)

Key: Biofrontera Bioscience GmbH (0) Acquired (4)

cls001 (3 trials)

digoxin (lanoxin) (4 trials)

ketoconazole (nizoral) (1 trial)

pefcalcitol (1 trial)

Drugs in Phase 1 Trials (1)

Key: Biofrontera Bioscience GmbH (0) Acquired (1)

imiquimod (aldara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Basal Cell (Phase 3)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 10